logo
It's National Eating Disorders Awareness Week, and it's more important than ever

It's National Eating Disorders Awareness Week, and it's more important than ever

Boston Globe25-02-2025

Get Winter Soup Club
A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter.
Enter Email
Sign Up
Meanwhile, social media is a double-edged sword. Yes, it offers more avenues for comparison and judgment — and unrealistic, doctored images on AI — but also more representations and narratives around diverse body shapes. Kids today are more exposed to language around body image than ever before, for better or for worse.
Advertisement
'That's a small positive: There's more awareness. I think the younger generation are more aware of diet culture, fat-shaming, and body positivity. They get it in ways that our generation, and our parents' generation, did not,' says Emily Gordon, a clinical psychologist in Natick who specializes in adolescent eating disorders.
Feb. 24-March 2 is National Eating Disorders Awareness Week. I talked to Alperovitz and Gordon about what to know, and how to help, if you suspect your child struggles with body image and eating.
On how eating disorders originate
: McLean is participating in a large-scale study examining genetic predisposition to eating disorders. For now, the current understanding is that they're multifactorial: 'There's a biological component. There's a psychological component. And, clearly, there's a social cultural component as well,' Alperovitz says. 'There's more research to be done around the biology and really determining vulnerabilities through DNA.'
Advertisement
We do know that younger people are especially susceptible because their bodies are changing so rapidly; life in general often feels overwhelming, and restricting eating can be a way to assert control.
'We can't take control of all the things that are going on in the world, but weight and food lends itself really nicely to being able to count calories or monitor in quantitative ways. It gives folks a sense of taking some control over a world that may feel largely beyond them,' he says.
Gordon sees patients whose eating disorders began because they were simply trying to boost confidence; eating healthfully was a self-esteem strategy that turned into a fixation.
'What happens is, people will turn to food and their body as a way of feeling good about themselves. We want people to have other ways of feeling good about themselves: People end up in trouble with an eating disorder when they've tried to be healthy, or they've tried to feel good, and then it's sort of gone awry. We really want to give people ways to regulate their systems, to express their feelings, and to not feel like they have to change themselves in order to be OK,' she says.
On misconceptions around eating disorders:
Eating disorders affect all sizes and genders. 'There's often a myth that eating disorders affect young, white, rich girls, not boys, and girls who are thin. That misses a lot,' Alperovitz says. 'Eating disorders affect people of all shapes, sizes, genders, sexual orientations, races. It really crosses the gamut. … They deserve support just as much as anyone.'
On red flags:
Be aware of how your kids approach their relationship to food. Do they restrict certain foods? Are they starting to avoid social situations for fear of judgment around body shape or size? Are they losing weight or avoiding certain places, like restaurants, to adhere to an eating plan?
Advertisement
'Exercise and eating healthy aren't bad things. But if they become compulsive and exist at the expense of other things that are meaningful, such as seeing friends and family, or being able to go to a certain place, then we're really crossing a line,' Alperovitz says.
Gordon looks for all-or-nothing thinking around food, and 'rigidity and lack of flexibility,' she says. 'It's so tricky, because in our culture, [eating healthfully] is idealized. Of course, we want people to be healthy. But when people start to do it in a rigid way, when people start cutting food out, when they start avoiding meals or snacks or having to exercise at the expense of other things in their lives,' there's a problem, she says.
On encouraging neutral conversations around size:
Gordon urges families to be aware of how they talk about bodies at home. It can be second nature to comment on someone's weight loss (especially with all the new drugs out there) or to remark that someone looks great if they've gotten thinner; the virtue of smallness is so ingrained in our culture.
It's also important to talk to kids about what they see on social media. For instance, a friend's daughter recently shared an Instagram account for her high school where people post Prom dress photos so nobody will overlap an outfit. Even the most benign comments focused on how people looked. Give your kids a safe place to share what it feels like to look at those photos and comments, even if you can't solve the problem.
Advertisement
'Ask: 'How does that make you feel when you see that? What do you think it's like for other kids?' We can engage with curiosity, and we can also have empathy. ... We can be there as a support and like a place for our kids to say, 'This is really hard,'' Gordon says.
On how to address a potential eating disorder:
Alperovitz stresses that there's often a secretive component to eating disorders; kids might not disclose an issue directly and won't respond well to confrontation.
Parents can set a subtly productive tone by having 'an inclusive approach to food, and seeing all foods as part of a spectrum,' he says. Be aware of using judgment-driven labels such as 'junk food.'
'They may not have as much nutritional value, but they're food, and they shouldn't be pathologized as evil,' he says. Kids can internalize that. If so, their eating could become dangerously restrictive.
'There are eating disorders that evolve out of a pure effort to be healthy, which is a really good thing, but then evolve to a point where it's so restrictive that they're in trouble nutritionally,' he says.
If you do notice a change in eating habits, he recommends approaching the issue directly, not at mealtime, from a place of curiosity.
'The more we walk on eggshells, the more we treat [an eating disorder] as a pathological thing that can't be talked about, and we almost reinforce secrecy around it. I would be kind, curious, and direct: 'Are you struggling? Are you missing things because of this?''
Hopefully, you can preempt an issue before it becomes severe, and your child will return to nourishing eating habits on their own. Providers encourage parents to look for small improvements: adding back in a restricted food; eating a bit more.
Advertisement
'But, again, eating disorders can often be secretive and shame-based, and it may be hard to talk with parents about. It may be easier to talk to a therapist or a primary care doctor around their relationship with food and their bodies,' Alperovitz says.
On finding help
. Therapy can be hard to find. In Massachusetts, the Multi-Service Eating Disorders Association (
Looking for a podcast? Gordon likes 'Maintenance Phase,' 'Burnt Toast,' 'Food Psych,' 'ED Matters,' and 'The Eating Disorder Recovery Podcast.'
And, if you're having a tough time finding a therapist who specializes in eating disorders, your child's primary care doctor is a good place to start. They can assess growth and evaluate overall health from a purely objective standpoint.
Kara Baskin can be reached at

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Spesolimab Provides Sustained Improvement of GPP and QOL
Spesolimab Provides Sustained Improvement of GPP and QOL

Medscape

time29-05-2025

  • Medscape

Spesolimab Provides Sustained Improvement of GPP and QOL

In a secondary analysis of phase 2b spesolimab data in generalized pustular psoriasis (GPP), nearly two-thirds of patients who received 300 mg monthly doses maintained clear or nearly clear skin through 48 weeks' follow-up, and nearly one quarter of treated patients maintained minimal GPP impact on quality of life (QOL). Nevertheless, investigators said, the presence of moderate QOL impairment despite clear or nearly clear skin at baseline highlighted the chronic nature of GPP and patients' need for effective long-term treatment. Similar observations emerged from a separate study that characterized GPP flares and treatment patterns. Skin Symptoms and QOL In the post hoc analysis of Effisayil 2 data, investigators led by Kenneth B. Gordon, MD, professor of dermatology, Medical College of Wisconsin, Milwaukee, found that overall, 20.0% of patients who received monthly subcutaneous spesolimab 300 mg (after a 600 mg subcutaneous loading dose) had sustained improvement in both GPP Physician Global Assessment (GPPGA) and Dermatology Life Quality Index (DLQI) scores through week 48 compared with 3.2% of the placebo cohort. Regarding skin manifestations, 63.3% of patients treated with spesolimab experienced sustained improvement, which investigators defined as having a GPPGA score of 0/1 at all Effisayil 2 study visits through week 48 without other investigator-prescribed medications. The corresponding figure among patients on placebo was 29.0%. The study recently appeared in the Journal of the American Academy of Dermatology ( JAAD ). As for QOL, 24.1% of spesolimab-treated patients maintained DLQI scores of 0/1 through week 48 vs 3.2% for placebo. Patients reported at baseline that GPP's biggest impact on QOL stemmed from itch, soreness, and pain; embarrassment; and the disease's effects on social activities and clothing choices. Although patients in Effisayil 2 had GPPGA 0/1 at baseline, Gordon and colleagues noted that the mean baseline DLQI scores of 11.1 and 7.2 in the 300 mg monthly and placebo groups, respectively, indicated that despite patients' having clear or nearly clear skin, moderate QOL burden persisted. Spesolimab, a monoclonal antibody that blocks interleukin (IL)-36 signaling known to be involved in GPP, was first approved by the US Food and Drug Administration in 2022 for treating flares in adults with GPP. Approval was expanded in 2024 for the treatment of GPP in adults and in pediatric patients aged ≥ 12 years who weigh ≥ 40 kg. Real-World Data In a separate study also recently published in JAAD , investigators found that among 638 eligible patients with GPP from the OMNY Health real-world data platform, 63% experienced at least one GPP flare between January 2017 and January 2023. The mean annualized flare rate was 0.91 per patient per year, with a mean inter-flare interval of 5.9 months. Patients who experienced flares were more likely to be women, younger than 65 years, non-White, Hispanic, or Latino, and had moderate or severe GPP and a history of infectious or parasitic disease. Treatment strategies were diverse, nonstandardized, and off-label, with patients frequently switching or discontinuing biologics and/or nonsteroidal systemic treatments. 'GPP patients continue to experience frequent flares with traditional off-label therapies in the real-world setting,' wrote authors led by Jamie W. Rhoads, MD, MS, of the University of Utah School of Medicine, Salt Lake City. Among patients who experienced multiple flares, they added, 66% had a second flare within 6 months of their first. Together, said James G. Krueger, MD, PhD, the D. Martin Carter professor in clinical investigation and co-director of the Center for Clinical and Translational Science at The Rockefeller University, New York City, the two papers examine how patients view their health status between flares and what the frequency of reflaring might be. He was not involved with the studies but provided comments in an interview with Medscape Medical News . Fear of Flaring Patients worry about GPP flares, said Krueger, because such flares constitute a medical emergency with potentially severe, life-threatening symptoms that could require hospitalization for weeks while receiving traditional immunosuppressants. And GPP is so rare that a practicing dermatologist may see only a few cases in their career. 'Given that almost no center takes in this type of patient,' he added, 'there's a lack of knowledge about the natural course of GPP and how best to manage patients with this disease.' James G. Krueger, MD, PhD Before spesolimab's approval for GPP, he said, broadly acting immunosuppressants targeted GPP indirectly. The fact that doctors could quell flares using such medications did not mean that patients' inflammation had resolved, Krueger added. 'It means their inflammatory state may have been suppressed to the point that they didn't need hospitalization. But many of these patients report significant symptoms or quality-of-life issues between flares.' Mechanistically, Krueger said, only around one quarter of patients with GPP possess a genetic mutation in a control protein called the IL-36 receptor antagonist, which normally would prevent the overblown IL-36 response that characterizes GPP. Nevertheless, he said, the mutation spotlights the IL-36 cytokine family as the most important, consistent aberration in causing GPP. 'This is one of the instances where a rare disease has a known genetic association, and that genetic problem can be fixed to a large extent by a therapeutic antibody. This antibody essentially replaces the function of the missing protein by binding to a receptor for IL-36 in a way that prevents it from being activated.' Accordingly, said Krueger, spesolimab approximates a molecular replacement therapy for GPP. 'And I believe that's why spesolimab works remarkably fast.' Ultimately, Krueger said, both articles mainly address medical dermatologists at referral centers who treat patients with more complicated GPP flares. 'The general practitioner should be aware that there are care pathways for acute and chronic GPP that may keep people under enough control that they can avoid recurrent emergency visits to either a dermatologist or an emergency room.' The new information about the likelihood that a patient will have lifelong disease 'helps with getting into the mindset that you're going to need to manage most of these patients over a long time period, not episodically,' he added. The spesolimab study was supported by Boehringer Ingelheim, maker of spesolimab; authors reported financial relationships with many companies that manufacture psoriasis drugs, including AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, and others. The second study was also supported by Boehringer Ingelheim. Rhoads had received consulting fees from Boehringer Ingelheim, Eli Lilly, and Genentech. Another author of the second study is an employee of OMNY Health, a contractor to Boehringer Ingelheim for the real-world study, and had received consulting fees from Boehringer Ingelheim, Eli Lilly, and Genentech. Two authors are Boehringer Ingelheim employees, and another author had received research grants and is a consultant to and had received honoraria from Boehringer Ingelheim. Krueger has been a consultant and lecturer for Boehringer Ingelheim and has analyzed biopsy samples from Effisayil 1 and 2 for future publications, but he is not an Effisayil author.

CraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"
CraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"

Associated Press

time29-05-2025

  • Associated Press

CraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"

BALTIMORE, May 29, 2025 /PRNewswire/ -- CraniUS Therapeutics, a cutting-edge medical device company advancing intracranial drug delivery, is proud to announce it has been voted the '2025 Emerging Life Sciences Company of the Year' by the Maryland Tech Council (MTC). The honor was presented during the Council's prestigious Industry Awards Celebration, which drew over 600 attendees, and recognizes the state's most innovative and impactful companies in technology and life sciences. The company's Founder and Executive Chairman, Dr. Chad Gordon, is a leader in Neuroplastic and Reconstructive Surgery. He serves as Section Chief and Fellowship Program Director at Johns Hopkins School of Medicine. Over his career, Dr. Gordon has secured 21 patents, led three successful venture exits, and conducted three first-in-human studies evaluating advanced cranial implants. His invention of the NeuroPASS™ device—CraniUS's core innovation—sparked the company's formation. This award acknowledges CraniUS's leadership and its groundbreaking development of the NeuroPASS™ platform, which enables direct, reliable delivery of therapeutics to the brain—addressing one of the most persistent challenges in treating brain tumors and other neurological conditions. 'We are honored to be recognized by the Maryland Tech Council with this year's Emerging Company Award,' said Dr. Gordon. 'This milestone reflects not only the dedication of our entire team but also the urgent need for transformative solutions in neurotherapeutics. We are extremely proud to be pioneering the new field of functional neurocranial implants inspired by Neuroplastic Surgery and driving this critical work forward—from right here in Maryland.' Mike Maglin, CEO of CraniUS Therapeutics, added, 'This award is a testament to the meaningful progress we've made and the momentum we've built—spanning scientific innovation, strategic alliances, and investor engagement. We remain committed to redefining how patients with neurological diseases receive life-changing medicines.' The Industry Awards Celebration is Maryland's premier event honoring excellence in technology, life sciences, and innovation. CraniUS was selected from a competitive field of nominees for its rapid growth, strong leadership, and the promise of its revolutionary device platform—employing patented neurotechnology—designed to reshape treatment approaches for conditions such as neurodegenerative diseases, movement disorders, and aggressive brain cancers. About CraniUS Therapeutics CraniUS Therapeutics is a neurotechnology company developing the first fully implantable platform to bypass the blood-brain barrier for long-term, programmable drug delivery. Its flagship device, NeuroPASS™, is designed to transform the treatment landscape for debilitating neurological conditions across multiple disease types. CraniUS Therapeutics is headquartered in Baltimore, Maryland, and collaborates globally with industry leading experts in neurosurgery, drug delivery, implant design, device engineering, and manufacturing. Media Contact: Elizabeth A. Dale, EdD Executive Advisor, CraniUS Therapeutics [email protected] 215-620-4482 View original content to download multimedia: SOURCE CraniUS Therapeutics

Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction

Yahoo

time28-05-2025

  • Yahoo

Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction

San Diego, CA, May 28, 2025 (GLOBE NEWSWIRE) -- Gordon Schanzlin New Vision Institute (GSNVI), a leading provider of advanced eye care in Southern California, is proud to announce it will soon offer Alcon's revolutionary Sitemap™ diagnostic platform, a major advancement in personalized refractive surgery. GSNVI will be the only practice in the region with access to this next-generation technology in 2025, giving patients an exclusive opportunity to experience a new era in vision correction. Developed by Alcon, the Sitemap system is designed specifically for patients with myopic astigmatism who are candidates for refractive procedures such as LASIK. Unlike traditional diagnostic tools, Sitemap builds a 3D model of each patient's unique eye anatomy, generating a customized laser shot pattern that is translated directly into a treatment plan—without manual input. This automated integration helps eliminate the possibility of transcription error, making the process safer, more sophisticated, and more precise. Dr. Michael Gordon, one of GSNVI's founding surgeons, played a direct role in the Sitemap clinical trials. 'This technology takes personalization to the next level,' said Dr. Gordon. 'Sitemap creates what I like to call an Eye-vitar—a digital fingerprint of your eye. The level of detail and customization allows us to design a vision correction plan that's tailored with extraordinary accuracy.' Patients at GSNVI will begin benefiting from Sitemap as early as June 2025, while competing practices will not have access to the platform until 2026. As a result, GSNVI remains at the forefront of innovation in refractive surgery and continues to attract patients seeking the most advanced solutions for vision correction. With multiple refractive options available—including LASIK, PRK, and EVO ICL™—the team at GSNVI believes the best procedure is always the one that's right for the individual. By incorporating Sitemap into the diagnostic process, the practice can now offer even greater personalization when determining each patient's ideal path to clear learn more about Sitemap technology or schedule a consultation, visit or call (858) Nancy Pursch - npursch@ Center Manager Gordon Schanzlin New Vision Institute 4130 La Jolla Village Drive, Ste 300 La Jolla, CA 92037 858-455-6800Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store